<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Genes involved in XY differences/disorders of sex development that are associated with atypical genital appearance</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Genes involved in XY differences/disorders of sex development that are associated with atypical genital appearance</h1>
<div class="graphic"><div class="figure"><div class="ttl">Genes involved in XY differences/disorders of sex development that are associated with atypical genital appearance</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="5" width="12%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Disorder<br/> (MIM phenotype)</td> <td class="subtitle1">Gene</td> <td class="subtitle1">Protein</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">Gonad</td> <td class="subtitle1">Müllerian structures</td> <td class="subtitle1">Associated features/variant phenotypes</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Global defects in testicular function (genes involved in gonadal development)</td> </tr> <tr> <td class="indent1"> <p><em>NR5A1</em> mutation</p> (<a href="https://www.omim.org/entry/612965" target="_blank">MIM #612965</a>)</td> <td><a href="https://www.omim.org/entry/184757" target="_blank"><em>NR5A1</em></a> (<em>SF1</em>)</td> <td>Nuclear receptor TF</td> <td>AD/AR</td> <td>Dysgenetic testis</td> <td class="centered">+/–</td> <td>Homozygous mutations associated with primary adrenal insufficiency. Heterozygous mutations are usually associated with isolated gonadal dysgenesis (although some cases with adrenal insufficiency have been reported). Asplenia may be present.</td> </tr> <tr> <td class="indent1"> <p><em>SRY</em>-related gonadal dysgenesis</p> (<a href="https://www.omim.org/entry/400044" target="_blank">MIM #400044</a>)</td> <td><a href="https://www.omim.org/entry/480000" target="_blank"><em>SRY</em></a></td> <td>TF</td> <td>Y</td> <td>Dysgenetic testis or ovotestis</td> <td class="centered">+/–</td> <td>Loss of <em>SRY</em> function can result in complete or partial testicular dysgenesis, XY ovarian DSD, or ovotesticular DSD.</td> </tr> <tr> <td class="indent1"> <p><em>SOX9</em> deficiency</p> (<a href="https://www.omim.org/entry/114290" target="_blank">MIM #114290</a>)</td> <td><a href="https://www.omim.org/entry/608160" target="_blank"><em>SOX9</em></a></td> <td>TF</td> <td>AD</td> <td>Dysgenetic testis or ovotestis</td> <td class="centered">+/–</td> <td>Camptomelic dysplasia (a skeletal dysplasia syndrome). 17q24 rearrangements have milder phenotype than point mutations.</td> </tr> <tr> <td class="indent1"> <p><em>WT1</em> mutation</p> <p>(<a href="https://www.omim.org/entry/194072" target="_blank">MIM #194072</a>, WAGR)</p> <p>(<a href="https://www.omim.org/entry/194080" target="_blank">MIM #194080</a>, Denys-Drash)</p> (<a href="https://www.omim.org/entry/136680" target="_blank">MIM #136680</a>, Frasier)</td> <td><a href="https://www.omim.org/entry/607102" target="_blank"><em>WT1</em></a></td> <td>TF</td> <td>AD</td> <td>Dysgenetic testis</td> <td class="centered">+/–</td> <td>Wilms tumor, kidney abnormalities, gonadal tumors (WAGR, Denys-Drash, and Frasier syndromes).</td> </tr> <tr> <td class="indent1"> <p><em>DHX37</em> mutation</p> (<a href="https://omim.org/entry/273250" target="_blank">MIM #273250</a>)</td> <td><a href="https://omim.org/entry/617362" target="_blank"><em>DHX37</em></a></td> <td>RNA helicase</td> <td>AD</td> <td>Dysgenetic testis or absent gonad</td> <td class="centered">+/–</td> <td>Also associated with testicular regression syndrome.</td> </tr> <tr> <td class="indent1"> <p><em>MAP3K1</em>-related gonadal dysgenesis</p> (<a href="https://www.omim.org/entry/613762" target="_blank">MIM #613762</a>)</td> <td><a href="https://www.omim.org/entry/600982" target="_blank"><em>MAP3K1</em></a></td> <td>Signal transduction</td> <td>AD</td> <td>Dysgenetic testis</td> <td class="centered"> </td> <td> </td> </tr> <tr> <td class="indent1"> <p><em>DHH</em>-related gonadal dysgenesis</p> (<a href="https://www.omim.org/entry/233420" target="_blank">MIM #233420</a>)</td> <td><a href="https://www.omim.org/entry/605423" target="_blank"><em>DHH</em></a></td> <td>Signaling molecule</td> <td>AR</td> <td>Dysgenetic testis</td> <td class="centered">+</td> <td>The severe phenotype of 1 patient included minifascicular neuropathy; other patients have isolated gonadal dysgenesis.</td> </tr> <tr> <td class="indent1"> <p><em>NR0B1</em> duplication</p> (<a href="https://www.omim.org/entry/300018" target="_blank">MIM #300018</a>)</td> <td><a href="https://www.omim.org/entry/300473" target="_blank"><em>NR0B1</em></a> (<em>DAX1</em>)</td> <td>Nuclear receptor TF</td> <td>dupXp21</td> <td>Dysgenetic testis or ovary</td> <td class="centered">+/–</td> <td> </td> </tr> <tr> <td class="indent1"> <p>Lissencephaly, X-linked 2</p> (<a href="https://www.omim.org/entry/300215" target="_blank">MIM #300215</a>)</td> <td><a href="https://www.omim.org/entry/300382" target="_blank"><em>ARX</em></a></td> <td>TF</td> <td>X</td> <td>Dysgenetic testis</td> <td class="centered">–</td> <td>X-linked lissencephaly, epilepsy, temperature instability.</td> </tr> <tr> <td class="indent1"> <p><em>ATRX</em>-related gonadal dysgenesis</p> (<a href="https://www.omim.org/entry/301040" target="_blank">MIM #301040</a>)</td> <td><a href="https://www.omim.org/entry/300032" target="_blank"><em>ATRX</em></a></td> <td>Helicase (chromatin remodeling)</td> <td>X</td> <td>Dysgenetic testis</td> <td class="centered">–</td> <td>Alpha-thalassemia, intellectual disability.</td> </tr> <tr> <td class="indent1"> <p><em>DMRT1</em>-related gonadal dysgenesis</p> (<a href="https://www.omim.org/entry/154230" target="_blank">MIM #154230</a>)</td> <td><a href="https://www.omim.org/entry/602424" target="_blank"><em>DMRT1</em></a></td> <td>TF</td> <td>Monosomic deletion, chromosome 9p24</td> <td>Dysgenetic testis</td> <td class="centered">+/–</td> <td>Intellectual disability.</td> </tr> <tr> <td class="indent1"> <p><em>PPP2R3C</em>-related gonadal dysgenesis</p> (<a href="https://www.omim.org/entry/618419" target="_blank">MIM #618419</a>)</td> <td><a href="https://www.omim.org/entry/615902" target="_blank"><em>PPP2R3C</em></a></td> <td>Protein phosphatase</td> <td>AR</td> <td>Dysgenetic testis</td> <td class="centered">+/–</td> <td>Characteristic facial features, cutaneous syndactyly, thick/stiff muscles, dry/scaly skin.</td> </tr> <tr> <td class="indent1"><em>SOX8</em></td> <td><a href="https://www.omim.org/entry/605923" target="_blank"><em>SOX8</em></a></td> <td>TF</td> <td>AD</td> <td>Dysgenetic testis</td> <td class="centered"> </td> <td> </td> </tr> <tr> <td class="indent1"> <p><em>WNT4</em> overexpression</p> (<a href="https://www.omim.org/entry/603490" target="_blank">MIM *603490</a>)</td> <td><a href="https://www.omim.org/entry/603490" target="_blank"><em>WNT4</em></a></td> <td>Signaling molecule</td> <td>dup1p35</td> <td>Dysgenetic testis</td> <td class="centered">+</td> <td>Intellectual disability.</td> </tr> <tr> <td class="indent1"> <p><em>ZFPM2</em> deficiency</p> (<a href="https://www.omim.org/entry/616067" target="_blank">MIM #616067</a>)</td> <td><a href="https://www.omim.org/entry/603693" target="_blank"><em>ZFPM2</em></a> (<em>FOG2</em>)</td> <td>Modulator of <em>GATA4</em> activity</td> <td>AD</td> <td>Gonadal dysgenesis</td> <td class="centered">+/–</td> <td>Dysgenetic gonads, rudimentary müllerian structures, learning and language difficulties (some patients).</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Disrupted müllerian inhibition</td> </tr> <tr> <td class="indent1"> <p>Persistent müllerian duct syndrome type 1</p> (<a href="https://www.omim.org/entry/261550" target="_blank">MIM #261550</a>)</td> <td><a href="https://www.omim.org/entry/600957" target="_blank"><em>AMH</em></a></td> <td>Signaling molecule</td> <td>AR</td> <td>Testis</td> <td class="centered">+</td> <td rowspan="2">External genitalia have typical male appearance, but there may be cryptorchidism. Persistent müllerian duct structures (uterus, fallopian tubes, and upper vagina).</td> </tr> <tr> <td class="indent1"> <p>Persistent müllerian duct syndrome type 2</p> (<a href="https://www.omim.org/entry/261550" target="_blank">MIM #261550</a>)</td> <td><a href="https://www.omim.org/entry/600956" target="_blank"><em>AMHR2</em></a></td> <td>Serine-threonine kinase transmembrane receptor</td> <td>AR</td> <td>Testis</td> <td class="centered">+</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Disorders of androgen synthesis</td> </tr> <tr> <td class="indent1"> <p>Leydig cell hypoplasia</p> (<a href="https://www.omim.org/entry/238320" target="_blank">MIM #238320</a>)</td> <td><a href="https://www.omim.org/entry/152790" target="_blank"><em>LHCGR</em></a></td> <td>G-protein receptor</td> <td>AR</td> <td>Testis</td> <td class="centered">–</td> <td>Range of phenotypes, depending on severity of LH/hCG receptor inactivation.</td> </tr> <tr> <td class="indent1"> <p>Smith-Lemli-Opitz syndrome</p> (<a href="https://www.omim.org/entry/270400" target="_blank">MIM #270400</a>)</td> <td><a href="https://www.omim.org/entry/602858" target="_blank"><em>DHCR7</em></a></td> <td>Enzyme (converts 7-dehydrocholesterol to cholesterol)</td> <td>AR</td> <td>Testis</td> <td class="centered">–</td> <td>Coarse facies, second-third toe syndactyly, failure to thrive, developmental delay, cardiac and visceral abnormalities.</td> </tr> <tr> <td class="indent1"> <p>17-beta-hydroxysteroid dehydrogenase type 3 deficiency</p> (<a href="https://www.omim.org/entry/264300" target="_blank">MIM #264300</a>)</td> <td><a href="https://www.omim.org/entry/605573" target="_blank"><em>HSD17B3</em></a></td> <td>Enzyme (converts androstenedione to testosterone)</td> <td>AR</td> <td>Testis</td> <td class="centered">–</td> <td>Partial virilization at puberty, elevated androstenedione:testosterone ratio.</td> </tr> <tr> <td class="indent1"> <p>5-alpha-reductase type 2 deficiency</p> (<a href="https://www.omim.org/entry/264600" target="_blank">MIM #264600</a>)</td> <td><a href="https://www.omim.org/entry/607306" target="_blank"><em>SRD5A2</em></a></td> <td>Enzyme (converts testosterone to dihydrotestosterone)</td> <td>AR</td> <td>Testis</td> <td class="centered">–</td> <td>Partial androgenization at puberty, elevated testosterone:dihydrotestosterone ratio.</td> </tr> <tr> <td class="indent1" colspan="7"><strong>Forms of CAH associated with underproduction of testosterone</strong></td> </tr> <tr> <td class="indent2"> <p>3-beta-hydroxysteroid dehydrogenase type 2 deficiency</p> (<a href="https://www.omim.org/entry/201810" target="_blank">MIM #201810</a>)</td> <td><a href="https://www.omim.org/entry/613890" target="_blank"><em>HSD3B2</em></a></td> <td>Enzyme (several steps in steroidogenesis)</td> <td>AR</td> <td>Testis</td> <td class="centered">–</td> <td>CAH, defective production of testosterone, but partial virilization caused by DHEA. Both XX and XY infants may have atypical genital appearance.</td> </tr> <tr> <td class="indent2"> <p>17-alpha-hydroxylase deficiency</p> (<a href="https://www.omim.org/entry/202110" target="_blank">MIM #202110</a>)</td> <td><a href="https://www.omim.org/entry/609300" target="_blank"><em>CYP17A1</em></a></td> <td>Enzyme (17-alpha-hydroxylase and 17,20-lyase)</td> <td>AR</td> <td>Testis</td> <td class="centered">–</td> <td>CAH, hypertension caused by corticosterone and 11-deoxycorticosterone (except in isolated 17,20-lyase deficiency).</td> </tr> <tr> <td class="indent2"> <p>P450 oxidoreductase deficiency</p> <p>(<a href="https://www.omim.org/entry/201750" target="_blank">MIM #201750</a>)</p> (<a href="https://www.omim.org/entry/613571" target="_blank">MIM #613571</a>)</td> <td><a href="https://www.omim.org/entry/124015" target="_blank"><em>POR</em></a></td> <td>CYP enzyme electron donor (cofactor for 21-hydroxylase, 17-alpha-hydroxylase, and aromatase)</td> <td>AR</td> <td>Testis</td> <td class="centered">–</td> <td>CAH, with mixed features of 21-hydroxylase deficiency, 17-alpha-hydroxylase/17,20-lyase deficiency, and aromatase deficiency; sometimes associated with Antley-Bixler craniosynostosis. Both XX and XY infants may have atypical genital appearance. May cause mild maternal virilization during pregnancy.</td> </tr> <tr> <td class="indent2"> <p>Lipoid CAH</p> (<a href="https://www.omim.org/entry/201710" target="_blank">MIM #201710</a>)</td> <td><a href="https://www.omim.org/entry/600617" target="_blank"><em>STAR</em></a></td> <td>Mitochondrial membrane protein (transports cholesterol to mitochondrion)</td> <td>AR</td> <td>Testis</td> <td class="centered">–</td> <td>CAH (primary adrenal failure), high risk for salt-losing crisis, typical female external genital appearance, absent or incomplete pubertal development.</td> </tr> <tr> <td class="indent2"> <p>P450scc deficiency</p> (<a href="https://www.omim.org/entry/613743" target="_blank">MIM #613743</a>)</td> <td><a href="https://www.omim.org/entry/118485" target="_blank"><em>CYP11A1</em></a></td> <td>Enzyme (converts cholesterol to pregnenolone)</td> <td>AR</td> <td>Testis</td> <td class="centered">–</td> <td>CAH, absent or incomplete pubertal development.</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Disorders of androgen insensitivity</td> </tr> <tr> <td class="indent1"> <p>Androgen insensitivity syndrome</p> (<a href="https://www.omim.org/entry/312300" target="_blank">MIM #312300</a>)</td> <td><a href="https://www.omim.org/entry/313700" target="_blank"><em>AR</em></a></td> <td>Nuclear receptor TF</td> <td>X</td> <td>Testis</td> <td class="centered">–</td> <td>PAIS presents with a range of phenotypes from largely female genital appearance (with mild virilization) to typical male genital appearance with infertility. Patients with CAIS have typical female external genital appearance.</td> </tr> </tbody></table></div><div class="graphic_lgnd">Chromosomal rearrangements likely to include key genes are included. Other genes that have been implicated but not definitively proven to be associated with DSD include <em>WWOX</em>, <em>GATA4</em>, <em>AKR1C2</em>, and <em>AKR1C4</em>.</div><div class="graphic_footnotes">AD: autosomal dominant (often de novo mutation); AR: autosomal recessive; CAH: congenital adrenal hyperplasia; CAIS: complete androgen insensitivity syndrome; DHEA: dehydroepiandrosterone; DSD: differences (or disorders) of sex development; hCG: human chorionic gonadotropin; LH: luteinizing hormone; PAIS: partial androgen insensitivity syndrome; RNA: ribonucleic acid; scc: side-chain cleavage; TF: transcription factor; WAGR: Wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome.</div><div class="graphic_reference">Adapted from:
<ol>
<li>Barbaro M, Wedell A, Nordenström A. Disorders of sex development. Semin Fetal Neonatal Med 2011; 16:119.</li>
<li>Lee PA, Houk CP, Ahmed SF, Hughes IA. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics 2006; 118:e488.</li>
</ol></div><div id="graphicVersion">Graphic 81145 Version 25.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
